Basic Information
Rasagiline ratiopharm
Regulatory Information
EMEA/H/C/003957
January 12, 2015
November 20, 2014
10
April 9, 2025
Company Information
Netherlands
Swensweg 5 2031 GA Haarlem
Teva Pharma B.V.
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Rasagiline ratiopharm is indicated for the treatment of idiopathic Parkinson’s disease (PD) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end of dose fluctuations.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Rasagiline ratiopharm. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Rasagiline ratiopharm. For practical information about using Rasagiline ratiopharm, patients should read the package leaflet or contact their doctor or pharmacist.